Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

We report the first case of lichen planus pemphigoides (LPP) secondary to ingestion of ramipril, an angiotensin-converting enzyme inhibitor. Clinical, histological and immunofluorescent findings were all consistent with a diagnosis of LPP. Linear basement membrane zone (BMZ) staining with IgG and C3 was only seen at the roof of split-skin preparations and circulating autoantibody to the BMZ was present at a titre of 1/100. Controlled immunoblotting of epidermal extracts detected the bullous pemphigoid antigens of 230 and 180 kDa.


Journal article


Br J Dermatol

Publication Date





412 - 414


Angiotensin-Converting Enzyme Inhibitors, Autoantibodies, Autoantigens, Carrier Proteins, Collagen, Cytoskeletal Proteins, Dystonin, Humans, Immunoblotting, Lichen Planus, Male, Middle Aged, Nerve Tissue Proteins, Non-Fibrillar Collagens, Ramipril, Skin, Skin Diseases, Vesiculobullous